GlassScriptPhysician profile
Jeffrey Lertdilok
NPI 1720621071
$2,457.01
in general payments reported to CMS, 2019-2025
25 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.46 · 2022: $267 · 2023: $343 · 2024: $714 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $665.08 | 2022-2025 | Fasenra, Saphnelo |
| Amgen INC. | $427.52 | 2021-2025 | Evenity, Prolia, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $231.00 | 2022-2025 | Vpriv, Hyqvia |
| Janssen Biotech, INC. | $202.59 | 2022-2025 | Tremfya |
| Tg Therapeutics, INC. | $178.92 | 2024-2025 | |
| Eisai INC. | $85.34 | 2023-2025 | |
| Tersera Therapeutics LLC | $78.28 | 2025 | Quzyttir |
| Alexion Pharmaceuticals, INC. | $57.67 | 2025 | Ultomiris |
| Lundbeck LLC | $55.86 | 2024-2025 | Vyepti |
| Abbvie INC. | $54.30 | 2022-2025 | |
| Organon LLC | $51.33 | 2022-2023 | Renflexis |
| Lilly USA, LLC | $48.38 | 2024 | Kisunla, Omvoh |
| Horizon Therapeutics Plc | $47.87 | 2022-2023 | Tepezza |
| Genzyme Corporation | $44.30 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.67 | 2024 | Spevigo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $26.51 | 2023 | Monoferric |
| Daiichi Sankyo INC. | $25.00 | 2023 | Injectafer |
| Invivyd INC | $24.43 | 2024 | Pemgarda |
| E.R. Squibb & Sons, L.L.C. | $24.10 | 2024 | Orencia |
| Viiv Healthcare Company | $23.30 | 2025 | Apretude |
| Hospira, INC. | $20.14 | 2024 | |
| Chiesi USA, INC. | $16.60 | 2025 | Elfabrio |
| Biogen, INC. | $15.77 | 2024 | Tysabri |
| Genentech USA, INC. | $12.72 | 2023 | Actemra |
| Adma Biomanufacturing LLC | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lertdilok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.